Kornimate/medical-research-clean huggingface dataset:
the effects of oral vitamin d supplementation on the prevention of peritoneal dialysis-related peritonitis

Conditions: Peritoneal Dialysis-associated Peritonitis; Vitamin D Deficiency

Summary: this is a pilot randomized, controlled trial of vitamin d supplementation in patients on peritoneal dialysis to determine the feasibility of a future full-scale rct exploring if oral administration of vitamin d3 could reduce the risk of subsequent peritoneal dialysis-related (pd-related) peritonitis. aims of the study: aim 1: to determine the feasibility of oral vitamin d supplementation among pd patients who have recovered from a recent episode of peritonitis. aim 2: to examine the effect of vitamin d supplementation on the risk for peritonitis among patients on peritoneal dialysis.

patients will be screened for eligibility one month after the onset of pd-related peritonitis, those who meet the inclusion criteria will be enrolled in this study. all consenting participants will be randomized into the vitamin d treatment group or the control group, general information and baseline biochemistry data would be collected. patients in the treatment group will be treated with oral cholecalciferol (2000iu/day) apart from routine treatment for pd. those in the control group will receive routine treatment for pd. both groups will be followed for 12 months. during the observational period, any onset of subsequent peritonitis will be recorded, serum 25(oh)d, biochemical indices will be measured every 3 months. follow up would take place frequently, any outcome events would be recorded. aims and hypotheses: aim 1: to determine the feasibility of oral vitamin d supplementation among pd patients who have recovered from a recent episode of peritonitis. hypothesis1: a large、full-scale randomized controlled trail on the effects of oral vitamin d on the risk for peritonitis among pd patients is feasible. aim 2: to examine the effect of vitamin d supplementation on the risk for peritonitis among patients on peritoneal dialysis. hypothesis 2: oral supplementation of vitamin d will reduce the risk of subsequent peritoneal dialysis.

Eligibility criteria:
inclusion criteria: 1. medically stable and receiving peritoneal dialysis (pd) for\>1 months 2. age at least 18 years. 3. serum 25(oh)d\<75nmol/l (30ng/ml) 4. adequate dialysis on evaluation, weekly kt/v ≥ 1.5 and no clinical uremic symptoms exclusion criteria: 1. receive vitamin d2/d3 or drugs known to alter serum 25-hydroxyvitamin d (25(oh)d) levels during the previous 12 months; 2. history of allergic reaction to cholecalciferol; 3. current or past malignant disease, active hepatitis or hepatic failure, acute systemic infection, active autoimmune diseases, severe digestive malabsorption or eating disorder, hiv/aids; 4. a high probability (assessed by the recruiting physician) of receiving a kidney transplant or transferring to hemodialysis (hd) or drop-out due to socioeconomic causes within 6 months; 5. pregnant or breastfeeding;

Keywords: cholecalciferol peritoneal dialysis peritonitis
monitoring and testing of blood pressure in postpartum women

Conditions: Hypertension

Summary: the purpose of this research study is to find out the usefulness of checking a woman's blood pressure remotely (at home) for 3 weeks after being discharged from the hospital after having a baby (or babies). some women can develop hypertension, or high bp, after delivery even if they have not had this problem before or during their pregnancy. untreated or unknown high bp can lead to medical complications, and if severe, can be life threatening. monitoring, or checking, remote bp after a woman has delivered her baby (or babies) has been suggested to be a better way to monitor bps without having to stay in the hospital for a longer time after delivery. other researchers report that women who have checked their bp remotely after delivery found out that this was both possible and acceptable.

this is a randomized control trial (rct). all women, 18 years of age and older, delivering an infant(s) at the birth center at atrium health wake forest baptist and residing in forsyth county, nc that have been approached by our home visit coordinators will be eligible for enrollment and invited to participate in the smart- bp study prior to discharge from the postpartum unit. per established protocols, the home visit coordinators for the nurse education support team program attempt to approach all women that deliver in the birth center and who reside in forsyth county. at this initial introduction, the home visit coordinators determine if the patient has any need for, or interest in, any of the vetted community resources available to her and her family. information about any of these resources are provided to the patient at that time. additionally, the home visit coordinators offer to schedule a nurse "home visit". this nurse home visit occurs via phone call, telehealth visit, or an in person visit \~2 weeks after delivery.

Eligibility criteria:
inclusion criteria: * women that received prenatal care at one of the atrium health wake forest baptist ob/mfm outpatient clinic locations in forsyth county, nc * women that delivered an infant(s) at the birth center at atrium health wake forest baptist * women that delivered an infant(s) at home or outside facility, and were transported to atrium health wake forest baptist and received postpartum care in the birth center * currently resides in forsyth county, nc * 18 years of age or older * able to read and understand either english or spanish * owns or has daily access to a smart phone (ios or android operating system) with available wi-fi or monthly mobile data plan exclusion criteria: * women that received postpartum care at any location other than the birth center at atrium health wake forest baptist * resides outside of forsyth county, nc * under 18 years of age * unable to read or understand either english or spanish * does not own or have daily access to a smart phone (ios or android operating system) with available wi-fi or monthly mobile data plan

Keywords: postpartum blood pressure women blood pressure monitoring
the effect of mobile application supported health promotion program on obesity of adolescents

Conditions: Adolescents; Mobile Application; School Health; Physical Activity; Nutrition Disorder, Child

Summary: the aim of the study is to evaluate the effectiveness of the child obesity program (cop), which is a school-based, parent-based, weight management program aimed mobile application at preventing overweight and obesity in childhood.

the aim of the study is to evaluate the effectiveness of the child obesity program (cop), which is a school-based, parent-based, weight management program aimed mobile application at preventing overweight and obesity in childhood. the program aims to provide children with positive health behaviors, gain cognitive and behavioral skills that will enable them to increase their knowledge of physical activity, nutrition and stress management.

Eligibility criteria:
inclusion criteria: obesity adolescents, smartphone internet, 10-16 years old exclusion criteria: non-obese child, 17 years old
maribavir for prevention of cmv after stem cell transplants

Conditions: Cytomegalovirus Infection

Summary: cytomegalovirus (cmv) infections remain a significant problem following various types of transplants that are associated with strong immunosuppressive therapy. maribavir is a new oral anti-cmv drug with a novel mechanism of action compared to currently available anti-cmv drugs. this study will test the safety and anti-cmv activity of different doses of maribavir when given as cmv prophylaxis following stem cell transplants.


Eligibility criteria:
inclusion criteria: * allogeneic stem cell transplant recipient * recipient cmv seropositive * have transplant engraftment * able to swallow tablets exclusion criteria: * cmv organ disease * hiv infection * use of other anti-cmv therapy post-transplant

Keywords: stem cell transplantation allogeneic transplantation
mxa-guided antiviral treatment in respiratory viral infections

Conditions: Respiratory Viral Infections; Influenza; SARS CoV-2

Summary: this pilot randomized controlled trial (rct) will investigate the clinical impact of myxovirus resistance protein a (mxa)-guided antiviral treatment versus standard treatment in patients with respiratory viral infections.

effective antiviral treatment would shorten the time to symptom resolution, accelerate the cessation of viral shedding, and improve the prognosis of respiratory viral infections. however, the optimal timing for antiviral treatment remains undetermined, and the current lack of objective biomarkers for respiratory viral infections often leads to either prolonged or insufficient antiviral treatment. thus, there is a need for strategies that incorporate novel diagnostics to guide antiviral treatment and provide more individualized therapy. myxovirus resistance protein a (mxa), a novel marker of viral infection, may hold potential in guiding antiviral therapy. in this pilot randomized controlled clinical study, we aim to evaluate whether mxa-guided antiviral treatment, as compared to standard care, can reduce the recurrence rate of respiratory viral infections and improve clinical outcomes

Eligibility criteria:
inclusion criteria: * ≥ 18 years old * with a primary diagnosis of influenza or covid-19 infection, diagnosed by a rapid antigen test or rt-pcr * duration of infection ≤14 days for non-severe patients and \< 28 days for patients with severe infections * currently receiving or planned to receive antiviral treatment, with the attending physician yet to decide on the discontinuation of the antiviral treatment exclusion criteria: * current endotracheal intubation and mechanical ventilation * current vasopressor use * known immunosuppression * received interferon therapy within 30 days before screening * systemic inflammatory responses within 30 days prior to screening, such as cerebral infarction, myocardial infarction, or surgery * received vaccine in the past 30 days * active tuberculosis * with contraindications for antiviral treatment * unable to obtain eligible samples * co-infected with influenza and covid-19
neurofeedback training for older adults with mild cognitive impairment: a pilot study

Conditions: Mild Cognitive Impairment

Summary: the purpose of this study is to evaluate the effects of smr neurofeedback training on cognitive performance and electrical brain activity in elderly with cognitive impairment.

older adults with mild cognitive impairment (mci) are at high risk to progress to alzheimer's disease (ad). slowing down effect of dementia by enhancing brain plasticity represents on of the most prominent challenges. neurofeedback is one of the promising techniques that showed therapeutic efficacy and cognitive improvement in attention-deficit hyperactivity disorder, epilepsy, stroke. the investigators aim to study the effects of a sensorimotor neurofeedback training protocol (smr) on cognitive performances in elderly and to assess whether mci patients change in brain electrical activity after training.

Eligibility criteria:
inclusion criteria: clinical diagnosis of mild cognitive impairment, educational level of 9 years of studies minimum, righthandedness, subjective memory complaint confirmed by an informant, a mini mental status examination score \> 20, preserve activity of daily living and absence of dementia. exclusion criteria: elderly persons who were under guardianship, resident in nursing facilities, neurological disease, psychiatric disease and involved in another cognitive intervention.

Keywords: mild cognitive impairment neurofeedback electroencephalography memory attention
sitagliptin combined with gemcitabine and albumin-bound paclitaxel in pdac patients

Conditions: PDAC - Pancreatic Ductal Adenocarcinoma

Summary: the purpose of this study is to determine the safety and tolerance of sitagliptin combined with gemcitabine and albumin-bound paclitaxel in subjects with locally advanced and metastatic pancreatic ductal adenocarcinoma.

this is a single-institution, prospective, open, one-armed phase ⅱ clinical trial of sitagliptin combined with gemcitabine and nab-paclitaxel. this study will enroll 30 pdac patients over 12-15 months.

Eligibility criteria:
inclusion criteria: 1.≥ 18 years old at the time of informed consent 2.ability to provide written informed consent and hipaa authorization 3.untreated locally advanced or metastatic pancreatic ductal adenocarcinoma (pdac) as defined by national comprehensive cancer network (nccn) guidelines or, untreated metastatic pdac (prior adjuvant therapy is permitted if it's been greater than 6 months since completion) 4.histologically or cytologically confirmed pdac 5.confirmed pdac that is measurable or evaluable per recist 1.1 6.eastern cooperative oncology group (ecog) performance status of 0-2 7.gastrointestinal symptoms (nausea, vomiting, and diarrhea) of grade 1 or less 8.adequate organ function as defined by: 1. aspartate transaminase (ast) and alanine transaminase (alt) levels ≤ 3 x upper limits of normal (uln) 2. total bilirubin level ≤ 2 x uln 3. creatinine level \ 30 kg/m2, lean body weight should be used to calculate the glomerular filtration rate (gfr). 4. hemoglobin (hgb) ≥ 90 g/l, absolute neutrophil count (anc) ≥ 1.5 x 109/l, platelets ≥ 80 x 109/l, acceptable coagulation studies as demonstrated by prothrombin time (pt) within normal limits (+/-15%) unless they are on anticoagulation therapy 5. life expectancy estimated at ≥ 3 months exclusion criteria: 1. with any cancer other than pdac in recent 5 years; 2. with myocardial infarction; 3. uncontrolled hypertension (systolic pressure\>150mmhg or diastolic pressure\>100mmhg after treatment) 4. lvef\<50% 5. history of hemorrhage or thromboembolism in the last 6 months 6. psychiatric history 7. pregnant or breastfeeding 8. interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung 9. autoimmune disease 10. uncontrolled active infection 11. other drugs that must be used during the trial may affect the metabolism of the experimental drugs (sitagliptin, gemcitabine, nab-paclitaxel)

Keywords: pdac sitagliptin
proton radiation therapy for macular degeneration

Conditions: Age-Related Macular Degeneration

Summary: this is a pilot study to determine if proton radiation therapy can provide effective and safe treatment for subfoveal neovascularization membrane (snvm). the study will include adult patients over the age of 50 with macular degeneration, who have subfoveal neovascularization membrane (snvm) and have had prior treatment with avastin or lucentis. additional purposes of this study are to see if the growth of neovascular membranes can be stopped and overall vision improved with the use of protons and assess the side effects associated with this treatment.

as part of this study, participants will have had a standard of care comprehensive eye exam by an ophthalmologist to include visual acuity, fundus photography, fluorescein angiography and optical coherence tomography prior to treatment. participants will receive radiation using protons for 2 consecutive days. each treatment will take 30 minutes. they will receive a total dose of 24 cobalt gray equivalent (cge) in 2 treatments. a total of 10 participants will be enrolled on this study. a comprehensive eye exam by an ophthalmologist will be performed 30 days after radiation treatment with protons. additionally, a physical examination per a radiation oncologist including a toxicity evaluation and comprehensive eye exam by an ophthalmologist will be performed every 3 months for 1 year following radiation treatment.

Eligibility criteria:
inclusion criteria: * patients with subfoveal neovascular membranes identified on fluorescein angiography. * visual acuity (best corrected vision) 20/200 or worse in affected eye. * patient must be 50 years of age or older at time of consent. * patients must have had prior treatment for macular degeneration with avastin (bevacizumab) or lucentis (ranibizumab). * women must be post menopausal or have had a hysterectomy. exclusion criteria: * history of diabetes.

Keywords: age-related macular degeneration macular degeneration proton radiation choroidal neovascular membranes
balance training for people with multiple sclerosis using nintendo wii fit

Conditions: Multiple Sclerosis

Summary: the aim is to evaluate balance training using nintendo wii fit. the hypothesis is that a period of training will increase balance capacity och self-efficacy. people with diagnosed multiple sclerosis are invited to participate. estimation of study power gave that 29 people in each group was necessary to detect a difference in the primary outcome measure, timed up and go test. other measures used are the four square step test, dynamic gait index, timed stands test, 25 foot walking test, 12-item walking scale and the abc scale. participants were randomised to either training or control. the training consisted of 6 weeks training with nintendo wii fit 30 minutes 2 times a week.


Eligibility criteria:
inclusion criteria: * diagnosed multiple sclerosis * subjective experience of affected balance and walking * being able to walk 100 meters with assistance exclusion criteria: * cognitive or language deficits that prevents using the self-rating scales * visual deficits that prevents training with television games * weight above 149 kg

Keywords: balance walking
the effects of nicotine chewing gum in parkinson's disease

Conditions: Low Blood Pressure; Parkinsons Disease

Summary: the objective of this experiment is: to determine if nicotine chewing gum will improve acute episodes of orthostatic hypotension in pd subjects.

subjects will be asked to sit and rest for 10 minutes. blood pressure will be taken in this resting position after the 10 minutes. after all inclusion criteria has been met, subjects will then wear an automated bp cuff and be administered 4mg of nicotine gum (nicorette™). they will be instructed to use it according to manufacturer's directions and remain chewing the gum for 30 minutes. the subject will remain in a seated position and bp and hr will be recorded every 5 minutes for 30 minutes. after 30 minutes the gum will be removed and subjects will still have hr and bp monitored in the seated position for another hour every 10 minutes. all values will be compared to pretreatment values. after 120 minutes if the subject is non-symptomatic, they can go home.

Eligibility criteria:
inclusion criteria: * a diagnosis of pd * a diastolic bp less than 90 mmhg * and/or a systolic bp lower than 100mhg. exclusion criteria: * current tobacco users in all forms of tobacco * severe dysphasia (difficulty swallowing) * previous tobacco users who might be at risk for re-addiction.
use of cbt-i based chatbot for assisted treatment in patients with insomnia

Conditions: Insomnia; Depression/Anxiety

Summary: the recent lifestyle has put many people in a state of high stress, and the outbreak of covid-19 in recent years has caused a steady increase in the number of people diagnosed with "coronasomnia" (covid-somnia) after recovering from the disease. for reasons outlined above, a lot number of people were suffering from insomnia. to propose some method to improve patients' sleep disorders become a popular research issue. the american academy of sleep medicine strongly recommends using the cognitive behavioral therapy for insomnia (cbt-i) method, one of the non-pharmacological treatments for insomnia. however, cbt-i is primarily a physical therapy, so patients may not be able to access this therapy due to time and location constraints. this project aims to combine the technology of cognitive behavioral therapy for insomnia (cbt-i) and chatbot to help insomnia patients learn more about their sleep habits and improve their sleep quality at home through remote access. investigators will design a friendly chatbot based on the cbt-i concept to assist insomnia patients to improve their sleep quality and life quality. this project will be executed at taipei municipal wanfang hospital. patients of insomnia will be referred by the attending physician from outpatient clinic. it is estimated that 120 patients will be enrolled, 60 in the experimental group and 60 in the control group. the experimental group will receive four weeks of cognitive behavioral therapy for insomnia via a chatbot, while the control group will be treated as usual. patients will be assessed for improvement in sleep severity at the end of four weeks and follow up after 12 weeks.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 2. significant insomnia symptoms, including difficulty initiating sleep, difficulty maintaining sleep, early-morning awakening. the sleep difficulty occurs at least three nights per week and is present for at least 3 months. 3. patient possess a personal internet-connected cell phone or communicator. exclusion criteria: 1. unwilling to participate in this research. 2. have poor cognitive function and cannot understand the content of the questionnaire; or cannot complete the test due to their physical condition 3. comorbid with schizophrenia, bipolar disorder, or substance use disorder 4. medications received have been adjusted in the past one month or will be adjusted during experiment 5. those who received in the past one month or will receive during experiment treatments such as: psychotherapy, cranial electrical stimulation, repetitive transcranial magnetic stimulation, transcranial direct current stimulation, or nutraceuticals aimed at improving mood or insomnia. 6. suicidal patients

Keywords: insomnia chatbot cbt cognitive behavioral therapy cognitive behavioral therapy for insomnia cbt-i
blood transfusions and immune response

Conditions: Infection After Transfusion; Transfusion-related Immunomodulation Reaction; Cytokine Storm; Surgery

Summary: * we have previously reported the results of the primary and secondary outcomes of a randomized study aiming to investigate the impact of a restrictive transfusion protocol on the magnitude of reduction in blood transfusion in a typically mixed general surgery population subjected to major abdominal surgery. * the main finding of that study was a reduction in red blood cell usage with the implementation of a restrictive transfusion regimen. this was achieved without adversely affecting clinical outcome in the population studied. * the aim of this secondary analysis performed on a subgroup of 20 patients from the original study was to determine whether there are any differences in the postoperative immunologic response, as expressed by the production of inflammatory mediators, between a restrictive approach to red cell transfusion and a more liberal strategy.


Eligibility criteria:
inclusion criteria: * adult patients, american society of anesthesiologists (asa) distribution i-iii, scheduled for elective upper major abdominal surgery exclusion criteria: * history of bleeding diathesis * hereditary hemostatic defects such as hemophilias * chronic anticoagulant administration * refusal of transfusions for religious reasons * ischemic heart disease (unstable angina or myocardial infarction within the last six months) * preexisting infectious diseases * preexisting autoimmune diseases * use of corticosteroids or immunosuppressive drugs within the last six months